SUMMARY Thirty seven Chinese adults and 23 children in Hong
Kong with myasthenia gravis were tested for HLA-A and -B antigens and acetylcholine receptor (AChR) antibody. HLA BW46 had a significantly increased prevalence in patients with juvenile onset ocular myasthenia gravis. Only one third of the juvenile ocular patients had AChR antibodies and the titres were generally low. In the adult patients taken as a whole there was a non-significant increase in the prevalence of HLA B5 and HLA B 15. HLA BW46 was more prevalent in adult patients without AChR antibody and less prevalent in patients with AChR antibody but the findings were not statistically significant. It is suggested that ocular myasthenia gravis is determined by a pathological mechanism for which susceptibility is determined by HLA BW46. There was a strong correlation between ocular myasthenia gravis and Graves' disease in the adult patients. The possibility that ocular myasthenia gravis is accentuated by a BW46-associated predisposition to ocular Graves' disease is considered. myasthenia gravis present in three of the adult patients. HLA BW46 which was previously shown to be associated with juvenile onset myasthenia gravis7 showed no obvious difference in prevalence in adult patients compared with controls (21-6% in patients, 26 4% in controls). There was an increased prevalence of both HLA B5 and HLA B15 in adult patients compared with controls but the differences were not statistically significant after adjustment for the number of antigens studied (HLA B5: 24-3% in patients, 9-1% in controls, 0-025 < p < 0-05 before adjustment. HLA B15: 324% in patients, 13-6% in controls, 0 01 < p < 0 025 before adjustment). Table I shows that 18 of the 21 adult patients with generalised disease had AChR antibody compared with 4 of the 13 with ocular disease. This difference was statistically highly significant (X2 = 8-34; 0 0025 < p < 0 005). The table also shows that 10 of the 13 adult patients with ocular myasthenia gravis had a history of Graves' disease compared with only three of 20 with generalised disease. This association was also statistically highly significant X1 = 10-19; 0 001 < p < 0-0025) and strongly supports the association between ocular myasthenia gravis and thyrotoxic Graves' disease found in other ethnic groups.'1 As expected, AChR antibody titres were generally much higher in the patients with generalised disease than in those with ocular disease. However, one patient with ocular disease (T2304) had an unusually high antibody titre but no evidence for disease involvement beyond the extra-ocular muscles.
In view of our previous suggestion7 that the presence of AChR antibody is related in some way to the host HLA phenotype, the frequencies of the HLA antigens of particular interest in adult patients with and without AChR antibody were compared in table 2. The frequencies of HLA B5 and HLA B15 were increased in patients with AChR antibody but not at a statistically significant level after adjustment for the number of antigens studied. There was an apparent increase in the prevalence of HLA BW46 in patients without AChR antibody and a decreased prevalence in patients with AChR antibody, which, although not statistically significant may have implications in view of the findings in the juvenile patients.
Of the 23 juvenile ocular myasthenics, seven had AChR antibody but the highest titre encountered was only 3 3 units. Twelve of the 16 There was no increase in the prevalence of HLA BW46 when the adult patients were studied as a whole. However, when the adult patients were separated on the basis of presence or absence of AChR antibodies there was an increased prevalence of HLA BW46 in patients without AChR antibody and a decreased prevalence in those with AChR antibody. These observations were not statistically significant after adjustment for the number of antigens studied. However, the lack of statistical significance does not necessarily exclude the biological significance of the observations in view of the findings in the juvenile patients. Over 65% of the juvenile ocular patients had HLA BW46 and only one third had AChR antibody. The antibody titres in the juvenile patients were noticeably lower than those encountered in the adult patients. Thus, the findings suggest that, both in adults and children, ocular myasthenia gravis and its accompanying absence or low titres of AChR antibody results from a pathological mechanism for which susceptibility is conferred by HLA BW46. This antigen is also known to be associated with thyrotoxic Graves' disease in Chinese, '4 and, as 
